Compare Davita Inc (DVA) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while JPMorgan Ultra Short Income ETF trades at $50.27 (market cap $42.37B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 3.8× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and JPMorgan Ultra Short Income ETF for 47 Days on average.
| DVA | JPST | |
|---|---|---|
Market Cap | $11.29B | $42.37B |
Volume | 582,204 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $50.78 |
52-Week Low | $103.87 | $50.22 |
Typical Hold Time | 114 Days | 47 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.27 with minimal daily movement (+0.04%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased holdings. The fund continues its regular $0.17 dividend payments, maintaining income distribution consistency.
JPST faces headwinds from rising interest rate environment while benefiting from demand for ultra-short duration strategies. The ETF's active management approach has shown recent underperformance versus peers, creating both opportunity for yield-seeking investors and risk from competitive pressure. Market volatility continues to drive flows into cash-alternative strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
